HOME >> BIOLOGY >> NEWS
HPV testing finds precancerous lesions at a higher rate than conventional pap smears

Human papillomavirus (HPV) testing was more sensitive than traditional Pap smears at detecting precancerous lesions of the cervix, a study in the June 7 issue of the Journal of the National Cancer Institute reports. A new, liquid-based form of the Pap test marginally improved sensitivity but also produced more false positives.

Previous studies have shown that searching for a precancerous cervical lesion called cervical intraepithelial neoplasia with an HPV test is more sensitive but also has more false positives than conventional pap smears, where doctors look for abnormal cells on a slide. Despite the widespread use of newer Pap technology called liquid-based cytology, where doctors first immerse the Pap sample in a solution before looking at the cells, its accuracy is not clearly defined. Some scientists suggest there is a need to understand what combination of tests increases sensitivity while keeping the number of false positives acceptable.

Guglielmo Ronco, M.D., Ph.D., of CPO Piemonte in Torino, Italy, and colleagues set up a randomized controlled trial that screened over 33,000 women for cervical cancer, half with conventional pap smears and the other half with HPV tests and liquid-based cytology. Women with abnormal cells from either Pap test or a positive HPV result were further examined by a technique called colposcopy, where doctors use a magnifying instrument to get a detailed view of the cervix.

The authors found that HPV testing combined with liquid-based cytology led to a 47% increase in sensitivity compared to conventional pap smears, but increased the chance of false positives by 60%. HPV testing alone increased sensitivity by more than 40%, with a smaller decrease in specificity (25% or 42%, depending on the type of test used). Liquid-based cytology did not show greater sensitivity than conventional pap smears, but increased the number of false positives.

The authors write, "HPV testing alone was more sensit
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jun-2006


Page: 1 2

Related biology news :

1. Modular leukemia drug shows promise in early testing
2. Rapid syphilis testing in Haiti will prevent congenital disease and stillbirths
3. XDx to present recent success with AlloMap molecular expression testing
4. Potential genetic testing for substance abuse raises hope, concern
5. U-M team: Genetic testing sheds light on degenerative eye disease
6. Antiretroviral resistance testing in HIV infected patients improves health and saves costs
7. Professors to develop hand-held pathogen testing device
8. Animal testing alternative has ticks trembling at the knees
9. New research to cut animal testing
10. New method of testing eggs for abnormalities could solve problems of embryo freezing
11. Education and guidelines needed for genetic testing in liver disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Over the ... into their drug discovery research workflows with biology ranging from single cell-type spheroids ... of in vitro studies, they create several challenges that need to be overcome ...
(Date:12/27/2018)... FRANCISCO (PRWEB) , ... December 27, 2018 , ... ... annual Microbiome Conference at JPM as part of the JP Morgan 37th Annual ... innovative scientists and physicians, and members of the investment community. , Since ...
(Date:12/20/2018)... ... December 20, 2018 , ... Human Factors and product ... a new usability/observation room. This addition will help meet the increased industry demand ... delivery devices/combination products are safe and easy to use when released to the ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... Fla. (PRWEB) , ... January ... ... Geometrical Implant Co, (SAGICO), an innovative spinal implant company, announced today that ... in San Francisco, California. The annual J.P. Morgan Healthcare Conference is ...
(Date:1/7/2019)... SEONGNAM, South Korea (PRWEB) , ... January 07, ... ... has completed Phase 1 clinical trials of its Parkinson's Disease drug candidate, code-named ... disease-modifying treatment of Parkinson's Disease. The trial took place in South Korea. ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, Inc., ... today announced the founding of a scientific and medical advisory board (SMAB). The ... leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT ... emerging biosciences ventures invited to participate in the annual program. Twelve ventures will ... plans and a professional network. All startups receive an entrepreneur coach, access to ...
Breaking Biology Technology:
Cached News: